Celldex Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Celldex Therapeutics generated cash of -$107,291,000, which is less than the previous year. Cash used in financing activities reached the amount of $218,458,000 last year. Net change in cash is therefore $5,385,000.
Cash Flow
| 2014 | -101.53M | -41.01M | 1.17M |
|---|---|---|---|
| 2015 | -98.88M | -50.19M | 193.15M |
| 2016 | -113.03M | 68.90M | 14.48M |
| 2017 | -99.93M | 46.46M | 51.29M |
| 2018 | -75.23M | 29.81M | 29.44M |
| 2019 | -46.41M | 17.08M | 16.25M |
| 2020 | -40.40M | -98.21M | 171.22M |
| 2021 | -60.90M | -216.15M | 272.37M |
| 2022 | -103.73M | 89.94M | 4.07M |
| 2023 | -107.29M | -105.78M | 218.45M |
CLDX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 29.42M | 39.14M | 43.83M | 11.23M | 24.31M | 40.28M | 42.46M | 72.10M | 28.02M | 169.40M |
Operating activities | ||||||||||
Net income | -141.42M | -112.32M | -70.51M | -59.78M | -50.87M | -151.18M | -93.03M | -128.53M | -127.19M | -118.08M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 3.00M | 2.89M | 3.06M | 3.92M | 4.85M | 3.80M | 5.31M | 4.09M | 4.01M | 3.40M |
Stock-based compensation expense | 23.89M | 15.61M | 8.95M | 3.91M | 4.55M | 0 | 12.31M | 15.31M | 12.77M | 6.85M |
| Deferred income tax benefit | 23.89M | 15.61M | 8.95M | 3.91M | 4.55M | 0 | 12.31M | 15.31M | 12.77M | 6.85M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -2.28M | -175K | 1.57M | -787K | -777K | -777K | -96K | -814K | -543K | 62K |
Inventories | 0 | 0 | 0 | 0 | 13.88M | 1.78M | -3.57M | -687K | 0 | 0 |
Accounts payable | 9.38M | 3.12M | 3.65M | 1.63M | -13.11M | -13.11M | -8.74M | -4.97M | 4.87M | 0 |
Cash generated by operating activities | -107.29M | -103.73M | -60.90M | -40.40M | -46.41M | -75.23M | -99.93M | -113.03M | -98.88M | -101.53M |
Investing activities | ||||||||||
Purchases Of Investments | -424.56M | -188.96M | -389.88M | -220.32M | -95.38M | -171.18M | -170.98M | -175.72M | -206.40M | -148.31M |
Investments In Property Plant And Equipment | -1.81M | -1.82M | -1.24M | -1.55M | -731K | -813K | -1.78M | -2.75M | -4.87M | -1.92M |
Acquisitions Net | 0 | 69K | 27K | 55K | 20K | 0 | 1.78M | 4.59M | 0 | 0 |
Cash generated by investing activities | -105.78M | 89.94M | -216.15M | -98.21M | 17.08M | 29.81M | 46.46M | 68.90M | -50.19M | -41.01M |
Financing activities | ||||||||||
Common Stock Issued | 216.22M | 4.07M | 269.89M | 171.22M | 16.24M | 29.02M | 51.02M | 13.94M | 188.84M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -2.96M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 218.45M | 4.07M | 272.37M | 171.22M | 16.25M | 29.44M | 51.29M | 14.48M | 193.15M | 1.17M |
Net Change In Cash | 5.38M | -9.71M | -4.69M | 32.60M | -13.07M | -15.97M | -2.17M | -29.64M | 44.08M | -141.38M |
Cash at end of period | 34.81M | 29.42M | 39.14M | 43.83M | 11.23M | 24.31M | 40.28M | 42.46M | 72.10M | 28.02M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |